Kuznicki Law PLLC notifies investors that a class action has commenced in the United States District Court for the Southern District of New York on behalf of shareholders of Zoetis, Inc. who purchased shares between January 14, 2025 and May 6, 2026.
Zoetis and certain of its executives are charged with failing to disclose material information during the Class Period concerning the growth, competitive positioning, market share, and veterinarian adoption of key products within the Companion Animal segment, violating federal securities laws.
The alleged false and misleading statements and/or omissions include, but are not limited to, that: (i) veterinarian prescription growth and adoption of the Company’s canine pain treatment, Librela, were stalling as clinicians became more cautious due to FDA safety warnings of serious neurological complications; (ii) Simparica Trio was losing significant market share to a lower priced competing canine parasiticide with broader indicated use in a slowing overall market; and (iii) the Company’s dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until July 27, 2026 to request that the court appoint them lead plaintiff.